Survival of Patients With Vancomycin-Resistant Enterococcus faecium Bacteremia Treated With Conventional or High Doses of Daptomycin or Linezolid Is Associated With the Rate of Bacterial Clearance

被引:13
作者
Chuang, Yu-Chung [1 ,2 ]
Lin, Hsin-Yi [3 ]
Chen, Pao-Yu [2 ]
Lin, Chi-Ying [4 ]
Chen, Yee-Chun [2 ]
Wang, Jann-Tay [2 ]
Chang, Shan-Chwen [2 ]
机构
[1] Natl Taiwan Univ, Coll Med, Grad Inst Clin Med, Taipei, Taiwan
[2] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei, Taiwan
[3] Natl Chengchi Univ, Dept Econ, Taipei, Taiwan
[4] Natl Taiwan Univ Hosp, Yun Lin Branch, Dept Internal Med, Yunlin, Taiwan
关键词
bacteremia; daptomycin; linezolid; outcome; real-time polymerase chain reaction; vancomycin-resistant enterococci; REAL-TIME PCR; STAPHYLOCOCCUS-AUREUS; CLINICAL-OUTCOMES; BLOOD CULTURES; MORTALITY; DNA; INFECTIONS; MODEL; PHARMACOKINETICS; INTERMEDIATE;
D O I
10.1097/CCM.0000000000003264
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Objectives: Vancomycin-resistant enterococci are important pathogens for healthcare-associated infections. Although linezolid is bacteriostatic and daptomycin is rapidly bactericidal against vancomycin-resistant enterococci in vitro, it is not clear whether they differ in their effect on bacterial clearance in patients with vancomycin-resistant enterococci bloodstream infections. Design: Prospective observational study. Setting: Two university hospitals and research laboratory. Patients: Patients with vancomycin-resistant enterococci bloodstream infection proven by blood cultures were prospectively enrolled from January 2010 to July 2015. Interventions: Sequential blood samples were collected. Real-time quantitative polymerase chain reaction was used to monitor bacterial loads. Measurements and Main Results: One hundred eight patients with vancomycin-resistant enterococci bloodstream infection were enrolled. Quantitative polymerase chain reaction assays were performed on 465 blood isolates. We found this method to be closely correlated with colony-forming units and more sensitive than culture. Sixty-three patients (58.3%) received conventional dose daptomycin (6-9mg/kg), 15 (13.9%) received high-dose daptomycin ( 9mg/kg), and 30 (27.8%) were treated with linezolid (600mg every 12 hr) as sole agents. The initial mean bacterial load was 1.03 log(10) copies/mL and unrelated to survival. Survivors had a more rapid early bacterial clearance than nonsurvivors ( log(10) copies/mL/d; -0.16 vs 0.31; p = 0.02). Multivariable logistic regression showed that a slower early bacterial clearance independently predicted increased mortality (odds ratio, 3.21; 95% CI, 1.03-10.02; p = 0.045). Conventional dose daptomycin was associated with a significantly slower rate of bacterial clearance than high-dose daptomycin ( log(10) copies/mL/d; -0.04 vs -0.41; p < 0.001) and linezolid (-0.04 vs -0.56; p = 0.043). Conclusions: We found that survivors of vancomycin-resistant enterococci bloodstream infection had a significantly more rapid early bacterial clearance by quantitative polymerase chain reaction than nonsurvivors. High-dose daptomycin and linezolid were associated with more rapid bacterial clearance than conventional dose daptomycin. These results support recommendations that conventional dose daptomycin not be used for the treatment of patients with vancomycin-resistant enterococci bloodstream infection.
引用
收藏
页码:1634 / 1642
页数:9
相关论文
共 49 条
[1]   Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations [J].
Akins, RL ;
Rybak, MJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (02) :454-459
[2]   Severe bacteremia results in a loss of hepatic bacterial clearance [J].
Ashare, A ;
Monick, MM ;
Powers, LS ;
Yarovinsky, T ;
Hunninghake, GW .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2006, 173 (06) :644-652
[3]   Chronic Liver Disease Impairs Bacterial Clearance in a Human Model of Induced Bacteremia [J].
Ashare, Alix ;
Stanford, Clark ;
Hancock, Patricia ;
Stark, Donna ;
Lilli, Kathleen ;
Birrer, Emily ;
Nymon, Amanda ;
Doerschug, Kevin C. ;
Hunninghake, Gary W. .
CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2009, 2 (03) :199-205
[4]   Systematic Review and Meta-Analysis of Linezolid versus Daptomycin for Treatment of Vancomycin-Resistant Enterococcal Bacteremia [J].
Balli, Eleni P. ;
Venetis, Chris A. ;
Miyakis, Spiros .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (02) :734-739
[5]   Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America [J].
Boucher, Helen W. ;
Talbot, George H. ;
Bradley, John S. ;
Edwards, John E., Jr. ;
Gilbert, David ;
Rice, Louis B. ;
Scheld, Michael ;
Spellberg, Brad ;
Bartlett, John .
CLINICAL INFECTIOUS DISEASES, 2009, 48 (01) :1-12
[6]   Comparative Effectiveness and Safety of Standard-, Medium-, and High-Dose Daptomycin Strategies for the Treatment of Vancomycin-Resistant Enterococcal Bacteremia Among Veterans Affairs Patients [J].
Britt, Nicholas S. ;
Potter, Emily M. ;
Patel, Nimish ;
Steed, Molly E. .
CLINICAL INFECTIOUS DISEASES, 2017, 64 (05) :605-613
[7]   Comparison of the Effectiveness and Safety of Linezolid and Daptomycin in Vancomycin-Resistant Enterococcal Bloodstream Infection: A National Cohort Study of Veterans Affairs Patients [J].
Britt, Nicholas S. ;
Potter, Emily M. ;
Patel, Nimish ;
Steed, Molly E. .
CLINICAL INFECTIOUS DISEASES, 2015, 61 (06) :871-878
[8]  
BRYAN CS, 1985, SURG GYNECOL OBSTET, V160, P557
[9]   Attributable mortality rate and duration of hospital stay associated with enterococcal bacteremia [J].
Caballero-Granado, FJ ;
Becerril, B ;
Cuberos, L ;
Bernabeu, M ;
Cisneros, JM ;
Pachón, J .
CLINICAL INFECTIOUS DISEASES, 2001, 32 (04) :587-594
[10]   Weight-adjusted versus fixed dose of linezolid for Chinese healthy volunteers of higher and lower body weight: a Phase I pharmacokinetic and pharmacodynamic study [J].
Cai, Yun ;
Chai, Dong ;
Falagas, Matthew E. ;
Karageorgopoulos, Drosos E. ;
Wang, Rui ;
Bai, Nan ;
Liang, Beibei .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2013, 22 (03) :309-315